AHA and ACC now tell doctors to treat high cholesterol earlier and more aggressively

Cumulative exposure is the stated rationale. The push toward earlier and more aggressive treatment rests on an observed relationship between how long cholesterol levels stay high and cardiovascular risk over a lifetime ^[4]. Short prediction windows sit badly with that logic. PREVENT-ASCVD, the calculator the guidelines encourage clinicians to use, returns a 10-year risk estimate starting at age 30 and a second estimate over the following 30 years ^[8]. For a 30-year-old, those windows close at 40 and at 60 ^[18].

The calculator estimates risk. It sorts patients into low, intermediate and high risk from inputs including body mass index, blood pressure, diabetes history, kidney function and smoking status ^[7], and the guidelines attach medication choices to that risk band ^[9]. How much a statin lowers one patient's absolute risk is a different quantity. The explainer, written by a cardiologist with expertise in sports and exercise science and published by The Conversation ^[19], describes the tools. It does not give the numeric cut-points, and it does not name the new studies behind them ^[20].

Two additions change what the office visit involves. Coronary artery calcium is new to the recommended assessment in this version ^[5], and the newer blood markers ApoB and Lp(a) sit alongside the standard LDL and HDL tests ^[6]. ApoB counts plaque-forming particles where LDL measures their mass ^[11]. In some scenarios, according to the explainer, ApoB predicts risk more accurately ^[12]. Whether treating to the new markers prevents more heart attacks than treating to LDL is a trial question, and LDL remains the traditional risk marker in the update ^[15].

The affected group is large. At least a quarter of Americans have dyslipidemia ^[13], the condition behind the plaque buildup that leads to heart attack and stroke ^[14]. Statins, atorvastatin and rosuvastatin among them, remain the standard of care ^[9], with other drug classes recommended when statins miss the goal or cause intolerable side effects ^[10]. Eight years separate this update from the 2018 version ^[17].

I expect the 30-year estimate to be the part that changes practice, mostly for patients in their thirties and forties whose 10-year number looks low. How far it goes depends on where the guideline sets its risk cut-points ^[9].